Weight Management
April 20, 2026
·
6 min read
read
Saxenda vs Ozempic: Comparing GLP-1 Injections for Weight Loss
If you've been researching medical weight loss options, you've almost certainly come across two names: Saxenda and Ozempic. Both are injectable GLP-1 receptor agonists. Both work by targeting hormones that regulate appetite and blood sugar. And both have clinical trial data showing meaningful weight reduction.
If you've been researching medical weight loss options, you've almost certainly come across two names: Saxenda and Ozempic. Both are injectable GLP-1 receptor agonists. Both work by targeting hormones that regulate appetite and blood sugar. And both have clinical trial data showing meaningful weight reduction.
But they are not the same medication — and the difference matters more than most comparison articles let on.
This guide breaks down what the clinical evidence actually shows, how the two drugs differ in mechanism and dosing, and what questions you should be asking before starting either one.
GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut after eating. It does several things simultaneously: it stimulates insulin secretion, suppresses glucagon (which raises blood sugar), slows gastric emptying, and — critically for weight management — signals to the brain that you're full.
GLP-1 receptor agonists are synthetic compounds that mimic this hormone. By binding to GLP-1 receptors throughout the body, they replicate and amplify its effects. The result is reduced appetite, slower digestion, improved glycaemic control, and — in many people — meaningful weight loss.
Liraglutide (Saxenda) and semaglutide (the active ingredient in Ozempic and Wegovy) are both GLP-1 receptor agonists, but they differ in molecular structure, half-life, dosing frequency, and the clinical outcomes observed in trials.
Saxenda contains liraglutide at a dose of 3.0 mg — a higher concentration than the 1.2 mg or 1.8 mg doses used in Victoza, the same molecule approved for type 2 diabetes management.
The key evidence base for liraglutide 3.0 mg in weight management comes from the SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial programme, a set of phase 3 randomised controlled trials published between 2015 and 2017.
In the landmark SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM, 2015), 3,731 adults without type 2 diabetes were randomised to liraglutide 3.0 mg or placebo, alongside lifestyle counselling. At 56 weeks:
These are clinically significant outcomes — a 5% reduction in body weight is associated with meaningful improvements in cardiometabolic risk factors. But they also set an important baseline: for a large proportion of patients, liraglutide produced moderate rather than dramatic weight loss.
Dosing: Saxenda is injected once daily, subcutaneously. Patients titrate up from 0.6 mg/day, increasing by 0.6 mg each week until reaching the 3.0 mg maintenance dose. This gradual titration is designed to reduce gastrointestinal side effects.
Half-life: Approximately 13 hours, which is why daily dosing is required.
Semaglutide has a longer half-life than liraglutide — approximately 7 days — which allows once-weekly dosing. Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) is approved in Singapore for type 2 diabetes management. Wegovy (semaglutide 2.4 mg) is the weight-management-specific formulation approved in some markets.
The evidence base for semaglutide in weight loss comes primarily from the STEP (Semaglutide Treatment Effect in People with Obesity) trial programme, published between 2021 and 2022.
In the pivotal STEP 1 trial (Wilding et al., NEJM, 2021), 1,961 adults with a BMI ≥30 (or ≥27 with at least one weight-related comorbidity) were randomised to semaglutide 2.4 mg weekly or placebo, plus lifestyle intervention:
STEP 2 examined patients with type 2 diabetes, showing 9.6% mean weight loss. STEP 4 demonstrated that weight regain occurred after discontinuation — an important consideration for long-term planning. STEP 5 showed sustained weight loss of approximately 15.2% at two years.
The STEP trial data represent a meaningful step-change in what medical weight management can achieve. A near-15% mean reduction approaches the outcomes historically associated with bariatric surgery in some populations.
Dosing: Semaglutide for weight management is titrated from 0.25 mg/week, increasing every four weeks to a maintenance dose of 2.4 mg/week (Wegovy) or the doses prescribed by your doctor for off-label or diabetes-indicated use.
| Saxenda (Liraglutide) | Ozempic/Wegovy (Semaglutide) | |
|---|---|---|
| Injection frequency | Once daily | Once weekly |
| Mean weight loss (trial) | ~8.0% (SCALE, 56 wks) | ~14.9% (STEP 1, 68 wks) |
| Half-life | ~13 hours | ~7 days |
| Primary approval | Weight management (3.0 mg) | T2DM (Ozempic); Weight (Wegovy) |
| Titration period | ~5 weeks | ~16–20 weeks |
Important caveat: Direct head-to-head trial comparisons between the two at equivalent doses don't exist in large populations. The efficacy differences observed across trials are significant and consistent with mechanistic differences, but trial populations, durations, and protocols differ. Your doctor will assess which option suits your specific profile.
Both drugs share a similar side effect profile, given their shared mechanism:
Common: Nausea, vomiting, diarrhoea, constipation, decreased appetite, injection site reactions. These are typically most pronounced during dose titration and often improve over time.
Less common but serious: Pancreatitis, gallbladder disease, tachycardia. Both carry a boxed warning (in FDA labelling) regarding thyroid C-cell tumours observed in rodent studies — the clinical significance in humans is uncertain, but both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
The incidence and severity of GI side effects may differ between individuals on the two drugs, but robust comparative data are limited. Some patients who experience significant nausea on one agent may tolerate the other better — this is an empirical question that should be managed with medical supervision.
This is a clinical decision, not a consumer choice. But broadly:
Saxenda (liraglutide 3.0 mg) has a longer track record, is an established option in many markets, and may suit patients who prefer a more gradual titration or who have concerns about weekly injection regimens.
Semaglutide shows greater mean weight loss in trials and a once-weekly dosing schedule that many patients find more convenient. It may be preferred for patients where greater weight reduction is clinically indicated.
Both require ongoing medical oversight. Neither is a standalone solution — lifestyle modification (diet, physical activity) remains a core component of any medically supervised weight management programme.
Q: Is Saxenda or Ozempic stronger for weight loss? A: Based on clinical trial data, semaglutide (Ozempic/Wegovy at 2.4 mg) produced greater mean weight loss (~14.9% in STEP 1) compared to liraglutide/Saxenda (~8.0% in SCALE Obesity and Prediabetes). However, individual responses vary and the right choice depends on your medical history, tolerability, and a doctor's assessment.
Q: Can I take Ozempic for weight loss if I don't have diabetes? A: Semaglutide 2.4 mg (Wegovy) is specifically indicated for chronic weight management. Ozempic (lower doses) is indicated for type 2 diabetes. Use of any GLP-1 medication for weight management should be under medical supervision. In Singapore, a licensed doctor must assess and prescribe.
Q: How long do I need to take these injections? A: GLP-1 receptor agonists are typically used as long-term treatments. STEP 4 data showed significant weight regain after discontinuation of semaglutide, suggesting that for many patients, sustained use is needed to maintain results. Your doctor will discuss duration with you based on your goals and health profile.
Q: What's the difference between Ozempic and Wegovy? A: Both contain semaglutide, but at different doses. Ozempic is approved for type 2 diabetes (0.5 mg, 1.0 mg, 2.0 mg weekly). Wegovy is approved specifically for weight management at 2.4 mg weekly. Availability of each formulation varies by market.
Q: Are GLP-1 injections safe? A: Both liraglutide and semaglutide have undergone extensive clinical evaluation. They carry known side effects (primarily GI-related) and specific contraindications. They are not appropriate for everyone. A doctor's assessment is essential before starting either medication.
Considering a GLP-1 programme in Singapore? Noah offers medically supervised weight management, including access to licensed doctors who can assess whether injectable GLP-1 therapy is appropriate for you. No obligation. Start with a consultation.
This article is for educational purposes and does not constitute medical advice. All medications require assessment and prescription by a licensed medical professional. Consult your doctor before starting any weight management treatment.
